Tulane Eosinophilic Disorder Center

Our Aim: Learn, Teach, Research and Cure

Home     Team      Research     Clinical     Contact      Donation 


Tulane Center for Eosinophilia Disorders under the leadership of Dr. Anil Mishra, PhD, is a first center of its kind in the southern region of the USA. The center will provide an opportunity for researchers, patients and their families to understand the disease and consult for better treatment of eosinophil associated disorders. The center will pulmdis purple cellsalso provide an opportunity for basic research scientists to directly translate their experimental findings of the human disease with the help of clinicians. The center will be involved in basic, clinical and translational studies to determine the mechanistic aspects of eosinophilic disorders in the lung, skin and multiple gastrointestinal segments. The center’s aim is to develop diagnostic and therapeutic interventions for eosinophil associated multiple diseases.

Eosinophilic disorders occur when eosinophils, white blood cells with a bilobed nucleus with multiple toxic granules, are found in above-normal amounts in various parts of the body. In a healthy state eosinophils reside in the gastrointestinal tract; however, during allergic (food or aeroallergen) responses, a large number of eosinophils are generated from their precursors in response to the stimulus and move into the sites (responsive organ of the body) and release a variety of toxins that can cause chronic inflammation, resulting in tissue damage and repair.

Eosinophils have a critical role in promoting asthma, dermatitis, multiple gastrointestinal disorders and tissue remodeling (fibrosis).

asthma fibrosis EOE

We and other investigators found that eosinophils have a major role in promoting asthma, dermatitis and a number of gastrointestinal symptoms. Because of our growing knowledge and better diagnostic technology, we now have a better understanding of a number of allergic diseases. We are currently studying multiple compounds that might block eosinophil production and their recruitment into the tissues. Our research work indicated that in future we could provide the best treatment for eosinophil-associated multiple medical disorders such as asthma, eosinophilic dermatitis, eosinophil associated gastrointestinal disorders and tissue remodeling (fibrosis).

Basic and Clinical Studies at Our Center

Dr. Mishra’s general research is aimed at deciphering mechanisms of inflammation, primarily based on discoveries concerning innate immunity. In particular, gene-environment interactions in the elicitation of inflammatory states in the respiratory and gastrointestinal tracts are under investigation. Environmental triggers (such as aeroallergens and food allergens) are studied in the context of specific genetic variants (e.g. IL-15 and IL-18 signaling) using population studies (cross sectional and longitudinal prospective cohorts) and mechanism-driven studies. The biological properties of innate inflammatory cells (eosinophil, mast cells, NKT cells, epithelial cells) and the cytokines (especially chemokines) that mediate their function are under investigation. The contribution of these basic processes to diverse human inflammatory conditions (e.g. asthma, eosinophil associated gastrointestinal disorders) is pursued by translational studies often involving unique clinical resources (e.g. patient samples and databanks) and clinical intervention studies (e.g. anti-cytokine therapeutics).

Principal Investigator

Anil Mishra, PhD,

Endowed Schlieder Chair and Professor of Medicine, Pulmonary Diseases, Director, Tulane Eosinophilic Disorder Center, Tulane Medical Center, New Orleans, LA 70112
Phone: 504-988-3840
Fax: 504-988-2144

Focus area of our research

Eosinophilic Gastrointestinal Disorders:

  • Eosinophilic esophagitis characterized by elevated levels of eosinophil in the esophagus;
  • Eosinophilic gastritis characterized by elevated eosinophil in the stomach;
  • Eosinophilic enteritis characterized by elevated eosinophil in the intestine;
  • Eosinophilic colitis characterized by excessive eosinophil in the colon.

Clinical Directors

  1. Ilana S. Fortgang, MD, Pediatric Gastroentrology and Hepatology, Tulane Medical Center, New Orleans, LA
  2. Monika Kowalczyk, MD, Adult Gastroentrology and Hepatology Section, Tulane Medical Center, New Orleans, LA
  • Asthma is a chronic inflammatory disease of the airways caused by a combination of genetic and environmental factors and characterized by airflow obstruction, and bronchospasm. Common symptoms include wheezing, coughing, chest tightness, and shortness of breath.
  • Clinical Director, Dr. Nereida Parada, MD, Associate Professor, Pulmonary Medicine. Tulane Medical Center, New Orleans, LA
  • Fibrosis is the formation of excess fibrous connective tissue in an organ or tissue in a reparative or reactive process. This can be a reactive, benign, or pathological state.
  • Clinical Director, Dr. Joseph Lasky, MD, Professor and Director, Pulmonary Medicine, Tulane Medical Center, New Orleans, LA

Fibrosis can occur in many tissues within the body, typically as a result of inflammation or damage, and examples include:

  • Pulmonary fibrosis (lungs) includes, idiopathic pulmonary fibrosis
  • Cystic fibrosis
  • Cirrhosis (liver)
  • Nephrogenic systemic fibrosis (skin)
  • Crohn's Disease (intestine)

Our Tulane Collaborators

  1. Dr. Luis Balart, MD, Professor and Director, Adult Gastroenterology and Hepatology Section, Tulane Medical Center, New Orleans, LA
  2. Dr. Robert Bulat, MD, Associate Professor and Director, Adult Gastroenterology and Hepatology Section, Tulane Medical Center, New Orleans, LA
  3. Jane M. El-Dhar, MD, Professor of Clinical Pediatrics and Clinical Professor of Medicine, Head, Section of Pediatric Allergy/Immunology/Rheumatology
  4. Dr. Laurianne Wild, MD, Professor and Director, Clinical Immunology, Tulane Medical Center, New Orleans, LA

  5. Off Site Collaborative Partners and Consultants
    1. Paul E. Hyman, MD, Professor Pediatrics, Division Head, Children’s Hospital, New Orleans, LA 70118. Email, Phone 504-896-9334, Fax 504-894-5567
    2. Sandeep K. Gupta, MD, Professor of Clinical Pediatrics & Clinical Medicine, Director, Pediatric Over Weight Education and Research Program, Riley Hospital for Children, Indianapolis, IN. Email
    3. Manoj R. Warrier, MD, Allergy, Asthma & Sinus Care Center 12818 Tesson Ferry Road, Suite #103, St. Louis, MO 63128. Phone 314-849-8700, Fax 314-849-8737, Email
    4. Hamid A. Boulares, PhD, Professor of Pharmacology and Experimental Therapeutics, Louisiana State University Health Sciences Center, New Orleans, LA 70112. Phone 504-210-2233, Email

Future Clinical Trials

  1. rIL-15 therapy for lung and esophageal fibrosis.
  2. rIL-15 therapy for airway restrictions (airway hyperactivity).
  3. Anti-CD1d and anti-Vα24Jα18 therapy to target iNKT cells for the treatment of eosinophilic esophagitis.

Patients and Family

Patients and families are encouraged to contact our center for any information needed to understand disease pathogenesis or treatment procedure for eosinophil related disorders.


Tulane Eosinophilic Disorder Center
Phone: 505-988-3840
Fax: 504-988-2144

Principal Investigator: Anil Mishra, PhD

Clinical Coordinator: Christine Glynn, RN
Phone: 504-988-0743


Funds needed for diagnostic and therapeutic interventions

Currently, we have very limited support from NIH and our research is very limited. We are in a need of funds to support our research program to find a permanent cure for eosinophil related lung skin and gastrointestinal disorders. We appeal to the general public and private funding agencies to provide the donations for our research programs.

Our research highlights:

  1. Aeroallergens promote asthma associated eosinophilic esophagitis. J Clin. Invest. 2001, 107, 83-90
  2. IL-15 has a critical role in EoE pathogenesis. Gastroenterology. 139, 182-92
  3. Peanut and corn allergen induce EoE pathogenesis is iNKT cell mediated. AJP-Gastroenterology and Liver Physiol. 2011, 302, G645-654
  4. mRNA levels of IL-15 responsive cell surface molecules and mediators are the novel noninvasive biomarkers for EoE that differentiate EoE from GERD (Patent publication WO 2013/155010A1#)
  5. rIL-5 treatment protects allergen-induced airway hyperactivity and tissue remodeling (fibrosis) in the lung and esophagus (Patent Filed)
  6. iNKT cell neutralization using monoclonal antibody for the treatment of eosinophilic esophagitis. Clinical and Translational Immunology. 2014
  7. Involvement of lL18 in eosinophilic esophagitis. Clinical Immunology 2015 and Immunology and Cell Biology 2015

1430 Tulane Ave, New Orleans, LA 70112 504-988-2250